Hyperuricemia
Conditions
Interventions
febuxostat group:febuxostat
Sponsors
the Affiliated Hospital of Qingdao University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Male and female aged 18 to 65 years; (2) patients with a diagnosis of and no history of renal replacement therapy; (3) patients with a diagnosis of HUA [sUA levels = 420 umol/L (7 mg/dL)in male and 360 umol/L in female]; (4) No urate lowering drugs were used before 1 month treatment.
Exclusion criteria
Exclusion criteria: 1. liver dysfunction (aspartate aminotransferase and/or alanine aminotransferase levels greater than two times the upper limit of institutional reference range); 2. gout, acute kidney injury, inflammatory disease, renal replacement therapy, active stage of peptic ulcer, malignancy, blood system disease, other serious disease; 3. received glucocorticoid/ immunosuppression therapy; 4. termination of treatment for personal reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum uric acid; | — |
Secondary
| Measure | Time frame |
|---|---|
| estimated glomerular filtration rate;Proteinuria; | — |
Countries
China
Contacts
Public ContactXuemei Liu
the Affiliated Hospital of Qingdao University
Outcome results
None listed